Last updated on April 2019

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma


Brief description of study

The purpose of this study is to evaluate the efficacy and safety of BGB-A317 as second line treatment in patients with advanced unresectable/metastatic ESCC that has progressed during or after first line therapy.

Clinical Study Identifier: NCT03430843

Contact Investigators or Research Sites near you

Start Over

St. Joseph Heritage Healthcare

Fullerton, CA United States
  Connect »

Millennium Oncology

Houston, TX United States
  Connect »

San Antonio Military Medical Center

Fort Sam Houston, TX United States
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.